Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Arcutis Biotherapeutics Inc
Net Income (Common)
Arcutis Biotherapeutics Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
Net Income (Common)
-$262.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Arcutis Biotherapeutics Inc's Net Income (Common)?
Net Income (Common)
-262.1m
USD
Based on the financial report for Dec 31, 2023, Arcutis Biotherapeutics Inc's Net Income (Common) amounts to -262.1m USD.
What is Arcutis Biotherapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-69%
Over the last year, the Net Income (Common) growth was 16%. The average annual Net Income (Common) growth rates for Arcutis Biotherapeutics Inc have been -25% over the past three years , -69% over the past five years .